Prescribing information (external link)
SCEMBLIX®▼ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and without a known T315I mutation.1
SCEMBLIX®▼ (asciminib) resources
SCEMBLIX® (asciminib) HCP downloadable resources
Explore our growing repository of resources designed to provide useful information on SCEMBLIX and other relevant topics for healthcare professionals treating patients with CML.
HCP quality of life tracker
HCP quality of life tracker
Support booklet for eligible patients prescribed SCEMBLIX
Support booklet for eligible patients prescribed SCEMBLIX
Support booklet for eligible patients prescribed SCEMBLIX
Please do not direct patients to this page. You can download this PDF and share this with your patients prescribed SCEMBLIX with CP Ph+ CML, to provide further information about their condition and useful advice about taking SCEMBLIX.
Support groups for your patients
Leukaemia Care
Leukaemia Care is a national blood cancer support charity. For over 50 years the Leukaemia Care team have been dedicated to ensuring that everyone diagnosed with leukaemia and related blood cancer types receives the best possible diagnosis and treatment. The organisation provides information, advice and support for patients, but also carers and families. Leukaemia Care team have created a variety of CML specific tools to help patients engage with the community and learn more about their diagnosis, including information booklets, support groups, webinars, as well as helpline, counselling and buddy programmes and other helpful platforms to support patients on their CML journey.
Blood Cancer UK
Blood Cancer UK is the UK’s largest blood cancer charity and offers comprehensive support for all types of blood cancer, including CML, for everyone affected by blood cancer. Blood Cancer UK offers trusted health information, practical and emotional assistance from blood cancer nurses via the phone or email, a clinical trials support service and an online community to connect with others affected by blood cancer. Its information covers a wide variety of topics including financial guidance and support for your carers and loved ones.
CML Support
Originally established in 1999 by two patients diagnosed with Ph+ CML, CML Support patient advocacy group provides support, advice and up-to-date information about the disease and its treatment options to patients diagnosed with CML. CML Support is the UK’s only charity with an exclusive focus on people diagnosed with Ph+ CML and run by patients on a voluntary basis. The group works alongside healthcare professionals to help patients get the best and most appropriate care possible and maintains links with other patient groups worldwide.
For further information, please refer to the Summary of Product Characteristics.
As this site grows, we will be adding lots of new content.
Sign up to receive our email communications and make sure you don’t miss the latest updates.
CML, chronic myeloid leukaemia; CP, chronic phase; HCP, healthcare professional; Ph+, Philadelphia chromosome positive; TKI, tyrosine kinase inhibitor.
Reference
SCEMBLIX (asciminib) Summary of Product Characteristics.
UK | January 2026 | FA-11572833
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
